ReviewBMC ophthalmology2025
Vision-threatening complications of injection sclerotherapy: case report, literature review, and FAERS database analysis.
Review in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundInjection sclerotherapy using sclerosants such as polidocanol has been widely employed for managing vascular disorders including chronic venous diseases and hemangiomas. Although sclerotherapy is considered a minimally invasive and generally safe procedure, rare but vision-threatening ocular complications have been reported. We present a unique scenario of progressive ophthalmic artery occlusion (OAO) associated with foamed polidocanol injection leading to irreversible blindness in a pediatric patient. CASE PRESENTATION: A 13-year-old male with a history of facial hemangioma underwent intralesional injection of foamed 1% polidocanol under ultrasound guidance at a dental clinic. He experienced transient monocular blindness in his left eye immediately after injection lasting for approximately 30 min, while best-corrected visual acuity at presentation recovered to 20/20. Despite systemic corticosteroids and anticoagulation, his vision deteriorated to no light perception within 1 month, accompanied by blepharoptosis and cutaneous necrosis. Multimodal imaging including fundus photography, optical coherence tomography, and fluorescein angiography demonstrated progressive retinal vascular occlusion, and Doppler ultrasonography at 1 month identified absent flow in the ophthalmic and central retinal arteries confirming OAO. Furthermore, a global pharmacovigilance analysis revealed that ocular complications represented only 3.9% of reported adverse events for sclerosing agents but were disproportionately severe, with 45.7% classified as death, life-threatening, disabling, or requiring hospitalization; permanent blindness occurred in 6.2% of the total cases.
conclusionsThis case underscores the potential for catastrophic ocular complications after polidocanol sclerotherapy. Given the limited therapeutic efficacy once iatrogenic OAO occurs, we emphasize caution when performing sclerosant injections particularly in the risky regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.